<DOC>
	<DOCNO>NCT03092791</DOCNO>
	<brief_summary>The purpose study select optimal antigen content three Sabin poliovirus strain ( type 1 , 2 , 3 ) enter composition stand-alone trivalent Sabin-based inactivated poliomyelitis vaccine ( sIPV ) take forward advanced stage study . The selection carry compare three sIPV study arm base safety tolerability profile dose primary immunization immune response poliovirus type 1 , 2 , 3 Sabin Salk strain , final dose three dose primary immunization series ( Day 85 ) .</brief_summary>
	<brief_title>IPV-102 Safety , Tolerability Immunogenicity TAK-195 Healthy Infants , Toddlers Adults</brief_title>
	<detailed_description>The drug test study call sIPV . sIPV use prevent poliomyelitis . This study look safety , tolerability sIPV healthy adult , toddler infant well immunogenicity toddler infant . . The study enroll approximately 340 participant include 40 adult , 60 toddler 240 infant . Adult participant randomly assign one two treatment groups—which remain undisclosed study doctor study ( unless urgent medical need ) : - sIPV High Dose - Placebo ( saline control - 0.9 % sodium chloride ) Toddler participant randomly assign one follow treatment group : - sIPV High Dose - Reference IPV Infant participant randomly assign one follow treatment group : - sIPV Low Dose - sIPV Medium Dose - sIPV High Dose - Reference IPV Adults toddler receive intramuscular injection Day 1 . Infants receive intramuscular injection Days 1 , 29 , 57 365 . This single center trial . The overall time participate study adult 8 day , toddler 183 day infant 547 day .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult Leadin Cohort 1 . Individuals good health time entry trial determine medical history , physical examination ( include vital sign ) clinical judgment investigator . 2 . Completed primary immunization poliomyelitis accord local recommendation . Toddler Leadin Cohort 1 . Toddlers good health time entry trial determine medical history , physical examination ( include vital sign ) clinical judgment investigator . 2 . Completed primary immunization poliomyelitis , preferably IPV , accord local recommendation . Infant Dose Ranging Cohort 1 . Infants good health time entry trial determine medical history , physical examination ( include vital sign ) clinical judgment investigator . 3 . Infants must bear full term ( 3742 week gestation ) . Adult Leadin Cohort 1 . Has body mass index ( BMI ) great equal 35 kg/m^2 ( = weight kg [ height meter * height meter ] . Toddler Leadin Cohort 1 . Last polio vaccination ( either inactivate oral ) receive within 5 month prior first trial visit . 2 . Household member/sibling receive is/are schedule receive Oral Poliomyelitis Vaccine ( OPV ) previous 3 month 5 week post participant 's inclusion study . 3 . Prior vaccination booster dose diphtheria , tetanus , pertussis ( acellular whole cell ) , polio ( either inactivate oral ) , Haemophilus influenzae type b ( Hib ) vaccine . Infant Dose Ranging Cohort 1 . Infants low birth weight accord local standard . 2 . Prior vaccination polio vaccine ( either inactivate oral ) . 3 . Household member/sibling receive is/are schedule receive OPV previous 3 month 5 week third dose primary immunization series . 4 . Prior vaccination diphtheria , tetanus , pertussis ( acellular whole cell ) , Haemophilus influenzae type b ( Hib ) vaccine polio vaccine ( OPV IPV ) . Note , BCG birth prior vaccination Hepatitis B vaccine give least 4 week prior first trial visit exclusion criterion . All Cohorts 1 . Any significant chronic infection . 2 . Any clinically significant active infection ( assessed investigator ) temperature ≥38.0°C ( &gt; 100.4°F ) , within 3 day intend trial vaccination . 3 . Known suspected impairment/alteration immune function , include : 1 . Chronic use oral steroid ( equivalent 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day ≥2 week ) within 60 day prior Day 1 ( use inhale , intranasal , topical corticosteroid allow ) . 2 . Receipt parenteral steroid ( equivalent 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day ≥2 week ) within 60 day prior Day 1 . 3 . Administration immunoglobulins and/or blood blood product within 3 month precede administration trial vaccine plan administration trial 4 . Receipt immunostimulants within 60 day prior Day 1 . 5 . Genetic immunodeficiency . 4 . Has know bleed diathesis , condition may associate prolonged bleeding time .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>